Literature DB >> 6185470

Buspirone: chemical profile of a new class of anxioselective agents.

D L Temple, J P Yevich, J S New.   

Abstract

Buspirone is a lipophilic, dibasic heterocyclic with no structural resemblance to other anxiolytic or antipsychotic agents. Neurochemical binding studies suggest that buspirone has both dopamine agonist and antagonist properties. Structural comparisons with (+)-butaclamol indicate that buspirone possesses features required for binding at the postsynaptic dopamine receptor site. This is consonant with the drug's biologic properties, but does not define a mechanism for its anxioselective action. The transient antipsychotic effect associated with peak blood levels of buspirone in rats was consistent with such an effect, predicted by [3H]spiperone binding studies. The low (20 mg) anxioselective dose, acting in concert with extensive metabolism in humans, produces low blood levels of the parent drug, suggesting that buspirone's effect is exerted through interactions with a high-affinity, low-threshold receptor system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6185470

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Buspirone in the treatment of levodopa induced dyskinesias.

Authors:  B Kleedorfer; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

2.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

Review 3.  Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.

Authors:  I Mahmood; C Sahajwalla
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

4.  Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.

Authors:  Rozita Davari-Ashtiani; Mahin Eslami Shahrbabaki; Katayoon Razjouyan; Homayoun Amini; Homa Mazhabdar
Journal:  Child Psychiatry Hum Dev       Date:  2010-12

5.  Clinical pharmacokinetics of oral buspirone in patients with impaired renal function.

Authors:  S Caccia; G L Vigano; G Mingardi; S Garattini; R E Gammans; M Placchi; R F Mayol; M Pfeffer
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

6.  Buspirone pharmacokinetics in patients with cirrhosis.

Authors:  K Dalhoff; H E Poulsen; P Garred; M Placchi; R E Gammans; R F Mayol; M Pfeffer
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

7.  Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus.

Authors:  R Andrade; R A Nicoll
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

8.  Conditioned taste aversion and place preference with buspirone and gepirone.

Authors:  J L Neisewander; S A McDougall; S L Bowling; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

9.  Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone.

Authors:  M Davis; J V Cassella; J H Kehne
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  Subchronic buspirone, mesulergine, and ICS 205-930 lack effects on D1 and D2 dopamine binding in the rat striatum during chronic haloperidol treatment.

Authors:  K A Young; R Zavodny; P B Hicks
Journal:  J Neural Transm Gen Sect       Date:  1991
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.